Medicus Pharma Ltd. celebrated its third anniversary by highlighting progress in transforming into a precision oncology-focused biotech company. The company advanced its portfolio with key assets like CD228V, an investigational antibody-drug conjugate targeting melanoma and other solid tumors, SkinJect for basal cell carcinoma in Gorlin syndrome patients, and Teverelix for urology and women's health. Medicus raised about $90 million through equity and debt to support clinical development and strategic acquisitions, aiming to build clinical evidence and attract partners. The company plans to focus on advancing clinical milestones, managing costs, and pursuing partnerships to enhance long-term value and capital efficiency.
Medicus Pharma's three-year progress is presented here alongside Pluang's health sector market snapshot as of Oct 08, 2026 18:43 WIB. Among 128 priced health-sector US stocks on Pluang, 29 rose and 91 fell today. Notable movers include DNA at USD 11.07 with a -3.49% change, MESO at USD 13.48 down by -3.30%, and SANA at USD 2.80 up by +2.94%.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
